scholarly journals Supplementation with cod protein hydrolysate in older adults: a dose range cross-over study

2019 ◽  
Vol 8 ◽  
Author(s):  
Caroline Jensen ◽  
Hanna F. Dale ◽  
Trygve Hausken ◽  
Einar Lied ◽  
Jan G. Hatlebakk ◽  
...  
Keyword(s):  
Older Adults ◽  
Glucose Metabolism ◽  
Mixed Model ◽  
Protein Hydrolysate ◽  
Dose Range ◽  
Serum Glucose ◽  
Secondary Outcome ◽  
Double Blind ◽  
Maximum Value ◽  
Postprandial Response

Abstract A large proportion of older adults are affected by impaired glucose metabolism. Previous studies with fish protein have reported improved glucose regulation in healthy adults, but the evidence in older adults is limited. Therefore, we wanted to assess the effect of increasing doses of a cod protein hydrolysate (CPH) on postprandial glucose metabolism in older adults. The study was a double-blind cross-over trial. Participants received four different doses (10, 20, 30 or 40 mg/kg body weight (BW)) of CPH daily for 1 week with 1-week washout periods in between. The primary outcome was postprandial response in glucose metabolism, measured by samples of serum glucose and insulin in 20 min intervals for 120 min. The secondary outcome was postprandial response in plasma glucagon-like peptide 1 (GLP-1). Thirty-one subjects aged 60–78 years were included in the study. In a mixed-model statistical analysis, no differences in estimated maximum value of glucose, insulin or GLP-1 were observed when comparing the lowest dose of CPH (10 mg/kg BW) with the higher doses (20, 30 or 40 mg/kg BW). The estimated maximum value of glucose was on average 0·28 mmol/l lower when the participants were given 40 mg/kg BW CPH compared with 10 mg/kg BW (P = 0·13). The estimated maximum value of insulin was on average 5·14 mIU/l lower with 40 mg/kg BW of CPH compared with 10 mg/kg BW (P = 0·20). Our findings suggest that serum glucose and insulin levels tend to decrease with increasing amounts of CPH. Due to preliminary findings, the results require further investigation.

The Efficacy of Lurasidone on PANSS Subscales in Adolescent Patients with Schizophrenia: Results from a 6-week, Double-blind, Placebo-controlled, Multicenter Study

2017 ◽  
Vol 41 (S1) ◽  
pp. S90-S91 ◽  
Author(s):  
C. Correll ◽  
R. Goldman ◽  
J. Cucchiaro ◽  
L. Deng ◽  
A. Loebel
Keyword(s):  
Repeated Measures ◽  
Mixed Model ◽  
Wide Spectrum ◽  
Dose Range ◽  
Data Safety Monitoring Board ◽  
Double Blind ◽  
Meaningful Improvement ◽  
General Psychopathology ◽  
Adolescent Patients ◽  
Adjusted Least Squares

IntroductionLurasidone is an atypical antipsychotic that demonstrated efficacy in the treatment of adults with schizophrenia in the dose range of 37–148 mg/day.Objective/AimsThe objective of this analysis was to evaluate the efficacy of lurasidone in adolescent patients with schizophrenia.MethodsAdolescents (13–17 years old) diagnosed with schizophrenia were randomly assigned to six weeks of double-blind treatment with lurasidone 37 mg/day, 74 mg/day or placebo. Changes from baseline to week 6 in PANSS total and subscale (positive, negative, general psychopathology, excitability) scores were evaluated using mixed-model repeated-measures analysis.ResultsA total of 326 patients (mean age, 15.4 years) were randomized and received lurasidone 37 mg/day (n = 108), 74 mg/day (n = 106), or placebo (n = 112). The PANSS total score at week 6 demonstrated a placebo-adjusted, least-squares (LS) mean improvement of –8.0 (P < 0.001; effect size [ES], 0.51) for the 37 mg/day group and –7.7 (P < 0.001; ES = 0.48) for the 74 mg/day group. Placebo-adjusted LS mean change for lurasidone 37 mg/day and 74 mg/day, respectively, was –3.2 (P < 0.001; ES = 0.62) and –3.2 (P < 0.001; ES = 0.60) on the PANSS positive subscale, –1.7 (P = 0.011; ES = 0.41) and –1.6 (P = 0.022; ES = 0.35) on the PANSS negative subscale, –2.8 (P = 0.012; ES = 0.38) and –2.8 (P = 0.011; ES = 0.37) on the PANSS general psychopathology subscale, and –1.1 (P = 0.016; ES = 0.36) and –1.8 (P < 0.001; ES = 0.53) on the PANSS excitability subscale.ConclusionsIn adolescent patients with schizophrenia, lurasidone (37 mg/day and 74 mg/day) demonstrated statistically significant efficacy and clinically meaningful improvement across a wide spectrum of symptoms associated with schizophrenia. Sponsored by Sunovion Pharmaceuticals Inc. ClinicalTrials.gov identifier: NCT01911429.Disclosure of interestDr Correll reports being a consultant and/or advisor for Alkermes, Forum Pharmaceuticals Inc., Gerson Lehrman Group, IntraCellular Therapies, Janssen/J&J, Lundbeck, Medavante, Medscape, Otsuka, Pfizer Inc, ProPhase, Sunovion Pharmaceuticals Inc., Supernus, Takeda, and Teva providing expert testimony for Bristol-Myers Squibb Company, Janssen, and Otsuka serving on a Data Safety Monitoring Board for Lundbeck and Pfizer Inc and receiving grant support from Takeda. Drs Goldman, Cucchiaro, Deng and Loebel are employees of Sunovion Pharmaceuticals Inc.

scholarly journals Effect of a cod protein hydrolysate on postprandial glucose metabolism in healthy subjects: a double-blind cross-over trial

2018 ◽  
Vol 7 ◽  
Author(s):  
Hanna Fjeldheim Dale ◽  
Caroline Jensen ◽  
Trygve Hausken ◽  
Einar Lied ◽  
Jan Gunnar Hatlebakk ◽  
...  
Keyword(s):  
Glucose Metabolism ◽  
Protein Hydrolysate ◽  
Postprandial Glucose ◽  
Mean Difference ◽  
Elderly Subjects ◽  
Healthy Individuals ◽  
Double Blind ◽  
Geometric Means ◽  
Breakfast Meal ◽  
Postprandial Insulin

AbstractThe increased prevalence of lifestyle diseases, such as the metabolic syndrome and type 2 diabetes mellitus (T2DM), calls for more knowledge on dietary treatments targeting the specific metabolic pathways involved in these conditions. Several studies have shown a protein preload before a meal to be effective in lowering the postprandial glycaemic response in healthy individuals and patients with T2DM. The aim of the present study was to assess the effect of a marine protein hydrolysate (MPH) from Atlantic cod (Gadus morhua) on postprandial glucose metabolism in healthy, middle-aged to elderly subjects. This double-blind cross-over trial (n 41) included two study days with 4–7 d wash-out in between. The intervention consisted of 20 mg of MPH (or casein as control) per kg body weight given before a breakfast meal. The primary outcome was postprandial response in glucose metabolism, measured by samples of serum glucose, insulin and plasma glucagon-like peptide 1 (GLP-1) in 20 min intervals for 180 min. In a mixed-model regression analysis, no differences were observed between MPH and control for postprandial glucose concentration (mean difference: −0·04 (95 % CI –0·17, 0·09) mmol/l; P = 0·573) or GLP-1 concentration (mean difference between geometric means: 1·02 (95 % CI 0·99, 1·06) pmol/l; P = 0·250). The postprandial insulin concentration was significantly lower after MPH compared with control (mean difference between geometric means: 1·067 (95 % CI 1·01, 1·13) mIU/l; P = 0·032). Our findings demonstrate that a single dose of MPH before a breakfast meal reduces postprandial insulin secretion, without affecting blood glucose response or GLP-1 levels, in healthy individuals. Further studies with repeated dosing and in target groups with abnormal glucose control are warranted.

scholarly journals Effect of a cod protein hydrolysate on postprandial glucose metabolism in healthy subjects: a double-blind cross-over trial — CORRIGENDUM

2019 ◽  
Vol 8 ◽  
Author(s):  
Hanna Fjeldheim Dale ◽  
Caroline Jensen ◽  
Trygve Hausken ◽  
Einar Lied ◽  
Jan Gunnar Hatlebakk ◽  
...  
Keyword(s):  
Glucose Metabolism ◽  
Healthy Subjects ◽  
Protein Hydrolysate ◽  
Postprandial Glucose ◽  
Double Blind

Effects of Aging on the Subcortical Encoding of Stop Consonants

2020 ◽  
Vol 29 (3) ◽  
pp. 391-403
Author(s):  
Dania Rishiq ◽  
Ashley Harkrider ◽  
Cary Springer ◽  
Mark Hedrick
Keyword(s):  
Older Adults ◽  
Repeated Measures ◽  
Mixed Model ◽  
Auditory Brainstem ◽  
Auditory Brainstem Responses ◽  
Aging Effects ◽  
Formant Frequency ◽  
Place Of Articulation ◽  
Second Formant ◽  
Effects Of Aging

Purpose The main purpose of this study was to evaluate aging effects on the predominantly subcortical (brainstem) encoding of the second-formant frequency transition, an essential acoustic cue for perceiving place of articulation. Method Synthetic consonant–vowel syllables varying in second-formant onset frequency (i.e., /ba/, /da/, and /ga/ stimuli) were used to elicit speech-evoked auditory brainstem responses (speech-ABRs) in 16 young adults ( M age = 21 years) and 11 older adults ( M age = 59 years). Repeated-measures mixed-model analyses of variance were performed on the latencies and amplitudes of the speech-ABR peaks. Fixed factors were phoneme (repeated measures on three levels: /b/ vs. /d/ vs. /g/) and age (two levels: young vs. older). Results Speech-ABR differences were observed between the two groups (young vs. older adults). Specifically, older listeners showed generalized amplitude reductions for onset and major peaks. Significant Phoneme × Group interactions were not observed. Conclusions Results showed aging effects in speech-ABR amplitudes that may reflect diminished subcortical encoding of consonants in older listeners. These aging effects were not phoneme dependent as observed using the statistical methods of this study.

scholarly journals Acute and Short-term Chronic Testosterone Fluctuation Effects on Glucose Homeostasis, Insulin Sensitivity, and Adiponectin: A Randomized, Double-Blind, Placebo-Controlled, Crossover Study

2014 ◽  
Vol 99 (6) ◽  
pp. E1088-E1096 ◽  
Author(s):  
Christian Høst ◽  
Lars C. Gormsen ◽  
David M. Hougaard ◽  
Jens S. Christiansen ◽  
Steen B. Pedersen ◽  
...  
Keyword(s):  
Molecular Weight ◽  
Glucose Metabolism ◽  
Crossover Study ◽  
High Molecular Weight ◽  
Glucose Disposal ◽  
Short Term ◽  
High Molecular Weight Adiponectin ◽  
Double Blind ◽  
Double Blind Placebo ◽  
Total Glucose

Context: Low levels of adiponectin and T in men have been shown to predict development of the metabolic syndrome, but the effects of T on glucose metabolism are incompletely understood and may be influenced either directly or indirectly through changes in body composition or in levels of adiponectin. Objective: The aim of the study was to test whether T exerts its effects on glucose metabolism directly or indirectly. Design, Setting, and Participants: In a randomized, double-blind, placebo-controlled, crossover study, 12 healthy young males were studied on four separate occasions. They received GnRH agonist treatment 1 month before 3 of 4 trial days to induce castrate levels of T. On trial days, T gel containing either high or low physiological T dose or placebo was applied to the body. On a fourth trial day, participants constituted their own eugonadal controls. Intervention: Each study comprised a 5-hour basal period and a 3-hour hyperinsulinemic euglycemic clamp. Main Outcome Measures: We measured the effect of acute T on peripheral glucose disposal, total adiponectin and subforms, and other indices of glucose metabolism. Results: Short-term hypogonadism was associated with increased high molecular weight adiponectin levels (P &lt; .03) and increased oxidative glucose disposal (P = .03) but not total glucose disposal (P = .07). Acute T treatment was an independent suppressor of high molecular weight adiponectin levels (P = .04) but did not affect total glucose disposal (P = .17). Conclusions: These data show that T can act through putative fast nongenomic pathways to affect adiponectin levels in humans. The early hypogonadal state is characterized by a marked shift in fuel oxidation from lipids toward glucose, which may rely partly on buffering capabilities of adiponectin.

scholarly journals PSX-7 Effect of varying levels of hempseed meal supplementation on animal performance, rumen fermentation, and blood metabolites of growing meat goats

2020 ◽  
Vol 98 (Supplement_4) ◽  
pp. 459-460
Author(s):  
Frank W Abrahamsen ◽  
Nar Gurung ◽  
Woubit Abdela ◽  
Gopal Reddy ◽  
Kim Mullenix
Keyword(s):  
Mixed Model ◽  
Average Daily Gain ◽  
Live Weight ◽  
Blood Chemistry ◽  
Optimal Level ◽  
Rumen Fermentation ◽  
Serum Glucose ◽  
Mixed Model Analysis ◽  
Meat Goats ◽  
Significant Difference

Abstract Hempseed meal (HSM) is a byproduct of hemp oil production and is high in crude protein, fiber, and fat, making it a potential feedstuff for ruminants. The objective of this study was to evaluate the effect of HSM supplementation on growth performance, rumen fermentation and blood chemistry profile of growing meat goats. Forty castrated, Boer cross goats were randomly assigned to one of the four treatments (n = 10): control, 10%, 20%, and 30% HSM supplementation. Data collected over a period of a 60-day feeding trial were analyzed utilizing the mixed model analysis function of SYSTAT, version 13. The result revealed total live weight gain decreased with the increasing levels of HSM supplementation 10.75, 9.53, 8.48, and 7.80 kg, for 0, 10, 20, and 30%, respectively. Average daily gain followed the same trend 0.179, 0.159, 0.141, and 0.13 kg, with a significant difference (P &lt; 0.05) observed between the control and 30 % supplementation. Conversely, feed to gain ratio increased with the increasing levels of supplementation 9.0, 10.2, 11.9, 12.2, likewise a significant difference was observed (P &lt; 0.05) between the control and 30% supplementation. Acetic, propionic, butyric, valeric, iso-valeric, and iso-butyric acid concentrations as well as the total VFA concentration decreased significantly (P &lt; 0.05) with the increasing level of supplementation. Acetic to propionic acid ratios increased with increasing level of supplementation 3.43, 4.36, 4.52, and 4.59, significant differences (P &lt; 0.05) were observed between control-20% and 30% HSM group. Serum glucose concentration decreased with an increasing rate of HSM supplementation while BUN concentration increased with no significant differences. These findings provide new insights into the feeding value of HSM for meat goats; however, further research needs to be conducted to determine the optimal level of supplementation.

Sign in / Sign up

Export Citation Format

Share Document